Thema: US8816242098
TEVA, US8816242098
amc-6295170_1920.jpg - Foto: THN
Teva stock faces emrusolmin trial setback as study is halted
Teva stock faces a pipeline setback after the company halted its emrusolmin study. The broader program remains under review.
ad-hoc-news.de, heute 11:01 Uhr
TEVA, US8816242098
Teva stock in focus after emrusolmin trial discontinuation ...
Teva stock faces a pipeline setback after an interim review found a low chance of meeting the study's main goal. No safety concerns were identified.
ad-hoc-news.de, 02.11.26 15:28 Uhr
TEVA, US8816242098
Teva stock in focus after BXCL501 rights deal
Teva stock is in focus after the company acquired a late-stage neuroscience candidate under FDA review. BXCL501 could bring acute agitation treatment into the home.
ad-hoc-news.de, 30.10.26 15:26 Uhr
TEVA, US8816242098
Teva acquires BXCL501 rights a USD 57.50 million test for ...
BXCL501 adds an investigational at-home treatment to Teva's neuroscience pipeline. Teva Pharmaceutical Industries stock faces a fresh pipeline test.
ad-hoc-news.de, 29.10.26 15:26 Uhr
TEVA, US8816242098
Fourteen brokerages set USD 46.08 target for Teva stock
Teva posted USD 4.14 billion revenue in the second quarter of 2026. Teva stock was USD 40.33 on October 27, 2026 at 10:25 a.m. ET, up 0.95 percent on NYSE.
ad-hoc-news.de, 27.10.26 15:26 Uhr
TEVA, US8816242098
Teva reports 44-week duvakitug data for Teva stock
Duvakitug retained 58 percent remission at Week 44. Teva stock enters November 3 results after USD 4.14 billion second-quarter revenue.
ad-hoc-news.de, 27.10.26 09:07 Uhr
TEVA, US8816242098
Zacks downgrades Teva stock to Strong Sell below yearly ...
Second-quarter revenue reached USD 4.15 billion, up 4.01 percent. Teva stock was USD 39.72 on October 26, 2026, up 0.79 percent from USD 39.41.
ad-hoc-news.de, 26.10.26 15:32 Uhr
TEVA, US8816242098
Piper Sandler sets USD 44.00 target for Teva stock ahead ...
Teva posted USD 4.14 billion revenue and a USD 576.00 million loss in the second quarter. Teva stock last stood at USD 39.41 on October 23, 2026.
ad-hoc-news.de, 26.10.26 09:17 Uhr
TEVA, US8816242098
Teva stock: At 4.31 percent below its high Teva stock traded ...
Barclays kept Overweight at USD 47.00 on October 15, 2026. Teva stock was USD 40.21 on October 22, 2026 at 4:00 p.m. ET, down 1.01 percent on NYSE.
ad-hoc-news.de, 23.10.26 15:08 Uhr
TEVA, US8816242098
Teva reports Uvakitug efficacy data. November 3 results ...
